Cervical cancer
Conditions
Interventions
CCRT:Cisplatin: 40 mg/m2 for 5 weeks
IMRT: PTV1 50-54 Gy
PTV2 45-48.6 Gy
PTV3 45-48.6 Gy
HDR brachtherapy: 24 Gy in 4 fractions
CCRT+E:Endostar 7.5 mg/m2/d from D1 to D14 for 2 cycles, starting on the first day of IMRT
Cisplatin: 40 mg/m2/w for 5 weeks
Sponsors
People's Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Ages between 18-70 years; 2. Histologically proven and newly diagnosed cervical squamous carcinoma or adenocarcinoma; 3. Sstages between IB2-IVA according to the FIGO Staging System (version 2014); 4. Performance status (PS) score 0-1; 5. Measurable lesion; no distant metastases confirmed by abdominal ultrasound, chest computed tomography (CT), and bone emission computed tomography (ECT); 6. Life expectancy >= 6 months; 7. Signed study-specific consent form; 8. White blood cell count >= 4.0 x 10^9 /L, platelet count >= 100 x 10^9 /L; 9. Normal prothrombin time; 10. Values of liver and renal functions <= 1.25 x upper normal limits; 11. Able to meet follow-up requirement.
Exclusion criteria
Exclusion criteria: 1. Distant metastases upon diagnosis; 2. Coexistence of other malignance; 3. Prior treatment with anti-tumor therapies, including RT, chemotherapy, and targeted therapy; 4. Contraindication to RT or chemotherapy, including severe infection, myocardial infarct, severe arrhythmia, severe cerebrovascular disease, mental disorder, and uncontrolled diabetes; 5. Lactating women; 6. Currently treated with other targeted therapy; 7. Patients currently in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;Acute toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;DMFS;LRRFS; | — |
Countries
China
Contacts
Public ContactHeming Lu
People's Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed